Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study.

Introduction: Patients with suspected inflammatory bowel disease (IBD) referred from primary care often face diagnostic and treatment delays. This study aimed to compare a novel direct-access IBD endoscopy pathway with the traditional care model.

Method: Single centre real-world study analysing primary care referrals with suspected IBD.

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].

Background And Aims: Subcutaneous [SC] vedolizumab presents the opportunity for inflammatory bowel disease [IBD] patients to manage their treatment at home. There are currently no data on the process of transitioning patients established on intravenous [IV] to SC vedolizumab as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC, at 12 weeks following the transition.

Life in lockdown: experiences of patients with IBD during COVID-19.

Objective: COVID-19 has disrupted the normal way of life in the UK, but for some patients with inflammatory bowel disease (IBD), the impact of this unprecedented global emergency was far greater. We aimed to assess the experience of patients with IBD during the COVID-19 lockdown.

Design: We designed a survey focused on the impact of COVID-19 on IBD healthcare, social and psychological well-being and quality of life.

High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning.

Background: Glucocorticosteroids (GC) are long-established, widely used agents for induction of remission in inflammatory bowel disease (IBD). Hyperglycaemia is a known complication of GC treatment with implications for morbidity and mortality. Published data on prevalence and risk factors for GC-induced hyperglycaemia in the IBD population are limited.

Early real-world effectiveness of ustekinumab for Crohn's disease.

Objective: To understand the effectiveness of ustekinumab in treating Crohn's disease (CD) in a UK real-world setting.

Design: Retrospective cohort study using prospectively maintained clinical records.

Setting: Single UK inflammatory bowel disease centre.

MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier.

Background And Aims: Mucosal healing is important in Crohn's disease therapies. Epithelial homeostasis becomes dysregulated in Crohn's, with increased permeability, inflammation, and diarrhoea. MicroRNAs are small non-coding RNAs that regulate gene expression and show changes in inflammatory bowel disease.

Biological therapy for the treatment of prepouch ileitis: a retrospective observational study from three centers.

Aim: Prepouch ileitis (PPI) is inflammation of the ileum proximal to an ileoanal pouch, usually associated with pouchitis. The treatment of PPI as a specific entity has been poorly studied, but it is generally treated concurrently with pouchitis. This to our knowledge is the largest study to explore the efficacy of biologics for the specific treatment of PPI.

Sniffing out causes of gastrointestinal disorders: a review of volatile metabolomic biomarkers.

Distinct changes can be observed in the odor of human excretions during health and disease. Identifying underlying volatile metabolites responsible for these odorous changes can be correlated with the pathological process within the body. Advances in the technology have enabled us to interpret the volatile signature of these changes in the odor.

MicroRNAs in inflammatory bowel diseases: paradoxes and possibilities.

MicroRNAs (miRNAs) are single-stranded RNA molecules, which influence the translation of messenger RNA and hence protein synthesis. The altered expression of miRNAs in disease states in cancer and autoimmune diseases including inflammatory bowel disease is providing new insights into disease pathogenesis. This understanding is leading to consideration of the utility of miRNAs in diagnostics, prognostics, and therapeutics in inflammatory bowel disease.

A case of cerebral amyloid angiopathy.

Unlabelled: BACKGROUND; Cerebral amyloid angiopathy (CAA) is a condition characterized by amyloid deposition in the walls of leptomeningal and cerebral cortical blood vessels. Clinically, CAA results in recurrent lobar haemorrhage that frequently presents with cognitive impairment or recurrent cerebral ischaemic events. CAA is widely believed to b eunder-diagnosed.